GB0325605D0 - Combination of organic compounds - Google Patents

Combination of organic compounds

Info

Publication number
GB0325605D0
GB0325605D0 GBGB0325605.4A GB0325605A GB0325605D0 GB 0325605 D0 GB0325605 D0 GB 0325605D0 GB 0325605 A GB0325605 A GB 0325605A GB 0325605 D0 GB0325605 D0 GB 0325605D0
Authority
GB
United Kingdom
Prior art keywords
combination
organic compounds
pharmaceutically acceptable
acceptable salt
diuretic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0325605.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29725841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0325605(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0325605.4A priority Critical patent/GB0325605D0/en
Publication of GB0325605D0 publication Critical patent/GB0325605D0/en
Priority to US10/577,370 priority patent/US20070072848A1/en
Priority to EP04797529A priority patent/EP1682122B9/en
Priority to BRPI0416154-8A priority patent/BRPI0416154A/pt
Priority to PCT/EP2004/012386 priority patent/WO2005049013A1/en
Priority to AU2004290505A priority patent/AU2004290505B2/en
Priority to KR1020067008517A priority patent/KR20060097025A/ko
Priority to ES04797529T priority patent/ES2303958T3/es
Priority to DE602004012593T priority patent/DE602004012593T2/de
Priority to AT04797529T priority patent/ATE389399T1/de
Priority to CA002544230A priority patent/CA2544230A1/en
Priority to PT04797529T priority patent/PT1682122E/pt
Priority to PL04797529T priority patent/PL1682122T3/pl
Priority to JP2006537238A priority patent/JP2007509900A/ja
Priority to CNA2004800329189A priority patent/CN1878548A/zh
Priority to RU2006119329/15A priority patent/RU2006119329A/ru
Priority to US12/286,039 priority patent/US20090036432A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0325605.4A 2003-11-03 2003-11-03 Combination of organic compounds Ceased GB0325605D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0325605.4A GB0325605D0 (en) 2003-11-03 2003-11-03 Combination of organic compounds
US10/577,370 US20070072848A1 (en) 2003-11-03 2004-02-11 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
CNA2004800329189A CN1878548A (zh) 2003-11-03 2004-11-02 AT1拮抗物、阿米洛利或triameterine与一种利尿剂的组合
RU2006119329/15A RU2006119329A (ru) 2003-11-03 2004-11-02 Комбинации ат1-антагонистов, амилорида или триаметерина, и диуретика
ES04797529T ES2303958T3 (es) 2003-11-03 2004-11-02 Combinaciones de valsartan, amilorida o triantereno y un diuretico.
AT04797529T ATE389399T1 (de) 2003-11-03 2004-11-02 Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum
PCT/EP2004/012386 WO2005049013A1 (en) 2003-11-03 2004-11-02 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic.
AU2004290505A AU2004290505B2 (en) 2003-11-03 2004-11-02 Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic.
KR1020067008517A KR20060097025A (ko) 2003-11-03 2004-11-02 Ａｔ１-길항제, 아밀로라이드 또는 트리아메테린, 및이뇨제의 배합물
EP04797529A EP1682122B9 (en) 2003-11-03 2004-11-02 Combinations of valsartan, amiloride or triamterine, and a diuretic
DE602004012593T DE602004012593T2 (de) 2003-11-03 2004-11-02 Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum
BRPI0416154-8A BRPI0416154A (pt) 2003-11-03 2004-11-02 combinação de antagonistas t1, amilorida ou triamterina, e um diurético
CA002544230A CA2544230A1 (en) 2003-11-03 2004-11-02 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
PT04797529T PT1682122E (pt) 2003-11-03 2004-11-02 Combinação de antagonistas at1, amiloride ou triantereno, e um diurético
PL04797529T PL1682122T3 (pl) 2003-11-03 2004-11-02 Kombinacja walsartanu, amiloridu lub triamterenu i diuretyka
JP2006537238A JP2007509900A (ja) 2003-11-03 2004-11-02 Ａｔ１−アンタゴニスト、アミロライドまたはトリアメテリンおよび利尿剤の組み合わせ
US12/286,039 US20090036432A1 (en) 2003-11-03 2008-09-26 Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0325605.4A GB0325605D0 (en) 2003-11-03 2003-11-03 Combination of organic compounds

Publications (1)

Publication Number Publication Date
GB0325605D0 true GB0325605D0 (en) 2003-12-10

Family

ID=29725841

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0325605.4A Ceased GB0325605D0 (en) 2003-11-03 2003-11-03 Combination of organic compounds

Country Status (16)

Country Link
US (2) US20070072848A1 (https=)
EP (1) EP1682122B9 (https=)
JP (1) JP2007509900A (https=)
KR (1) KR20060097025A (https=)
CN (1) CN1878548A (https=)
AT (1) ATE389399T1 (https=)
AU (1) AU2004290505B2 (https=)
BR (1) BRPI0416154A (https=)
CA (1) CA2544230A1 (https=)
DE (1) DE602004012593T2 (https=)
ES (1) ES2303958T3 (https=)
GB (1) GB0325605D0 (https=)
PL (1) PL1682122T3 (https=)
PT (1) PT1682122E (https=)
RU (1) RU2006119329A (https=)
WO (1) WO2005049013A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
WO2012152718A1 (en) 2011-05-06 2012-11-15 Farmicom Pharmaceutical Company D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
CN102793703A (zh) * 2011-05-25 2012-11-28 苏州洪瑞医药科技有限公司 一种盐酸阿米洛利和环戊噻嗪的药物组合物及其制备方法
WO2018027550A1 (en) * 2016-08-09 2018-02-15 Shanghai Yao Yuan Biotechnology Co., Ltd. Methods and compositions for appetite control and weight management
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040087484A1 (en) * 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
ATE389399T1 (de) 2008-04-15
AU2004290505A1 (en) 2005-06-02
ES2303958T3 (es) 2008-09-01
PL1682122T3 (pl) 2008-09-30
AU2004290505B2 (en) 2007-09-20
DE602004012593D1 (de) 2008-04-30
CN1878548A (zh) 2006-12-13
EP1682122B1 (en) 2008-03-19
US20070072848A1 (en) 2007-03-29
RU2006119329A (ru) 2007-12-27
WO2005049013A1 (en) 2005-06-02
CA2544230A1 (en) 2005-06-02
BRPI0416154A (pt) 2007-01-09
EP1682122A1 (en) 2006-07-26
EP1682122B9 (en) 2009-04-08
DE602004012593T2 (de) 2009-04-23
KR20060097025A (ko) 2006-09-13
US20090036432A1 (en) 2009-02-05
PT1682122E (pt) 2008-06-18
JP2007509900A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
AU2003246811A8 (en) Terphenyl derivatives, preparation thereof, compositions containing same
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
TW200700406A (en) Novel thiophene derivatives
WO2003095455A3 (en) Substituted pyrazolopyrimidines
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
MY137535A (en) New pyrrolidinium derivatives
TW200708511A (en) Novel thiophene derivatives
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2001076574A3 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
EP1630157A4 (en) ANTAGONIST OF CASR
UA94065C2 (en) Dihydropseudoerythromycin derivatives
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
BR0317555A (pt) Composições farmacêuticas de sertaconazol para uso vaginal
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
PL372457A1 (en) New pharmaceutical compositions containing flibanserin polymorph a
WO2006039163A3 (en) Cyclosporin alkyne analogues and their pharmaceutical uses
PA8649901A1 (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
WO2005117895A8 (en) Compositions comprising meloxicam
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
GB0212410D0 (en) Organic compounds
GB0325605D0 (en) Combination of organic compounds
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)